Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Case Report: Warfarin-Induced Non-Uremic Calciphylaxis Mimicking Vasculitis

Marie Dardeno, DO, Joshua D. Sparling, MD, & William Monaco, MD  |  Issue: May 2021  |  

William Monaco, MDWilliam Monaco, MD, is a rheumatologist practicing in Augusta, Maine. He completed his internal medicine residency and rheumatology fellowship at Dartmouth-Hitchcock Medical Center in Lebanon, N.H.

References

  1. Nigwekar SU. Calciphylaxis. Curr Opin Nephrol Hypertens. 2017 Jul;26(4):276–281.
  2. Chang JJ. Calciphylaxis: Diagnosis, pathogenesis, and treatment. Adv Skin Wound Care. 2019 May;32(5):205–215.
  3. Schurgers LJ, Cranenburg ECM, Vermeer C. Matrix Gla-protein: The calcification inhibitor in need of vitamin K. Thromb Haemost. 2008 Oct;100(4):593–603.
  4. Bajaj R, Courbebaisse M, Kroshinsky D, et al. Calciphylaxis in patients with normal renal function: A case series and systematic review. Mayo Clin Proc. 2018 Sep;93(9):1202–1212.
  5. Yu WY, Bhutani T, Kornik R, et al. Warfarin-associated nonuremic calciphylaxis. JAMA Dermatol. 2017 Mar 1;153(3):309–314.
  6. Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol. 2008 Mar;58(3):458–471.
  7. Nigwekar SU, Brunelli SM, Meade D, et al. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013 Jul 3; 8(7): 1162–1170.

Related Articles

    Case Report: Refractory Calciphylaxis in Lupus

    Calciphylaxis is a poorly understood and life-threatening ischemic vasculopathy characterized by calcification of the small- and medium-size arteries in the skin, subcutaneous tissue and internal organs, which leads to thrombosis, tissue necrosis and painful skin ulcerations that won’t heal. The disease has a 50–80% mortality rate. Although affected patients typically have end-stage renal disease (ESRD)…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…